C4 Therapeutics, Inc. (CCCC): who owns it and who trades it
As of Nov 13, 2026, CCCC insiders reported 2 open-market sales worth $145K and no purchases in the last 12 months, with 85% of the sale value made under pre-set 10b5-1 plans. The largest seller was Kendra Adams (CFO), with $122K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 13, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling C4 Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CCCC
147 funds and institutions reported CCCC shares worth $551M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Morgan Stanley with 8.0%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Morgan Stanley | 8.87M | 8.02% | $41.4M | -2% |
| Ra Capital Management, L.P. | 8.00M | 7.24% | $37.4M | No change |
| BlackRock, Inc. | 7.90M | 7.14% | $36.9M | +285% |
| Lynx1 Capital Management LP | 7.33M | 6.63% | $34.2M | +5% |
| Squadron Capital Management LLC | 7.20M | 6.51% | $33.6M | +220% |
| Bain Capital Life Sciences Investors, LLC | 7.17M | 6.49% | $33.5M | No change |
| JPMorgan Chase & Co | 4.75M | 4.29% | $20.7M | – |
| Vanguard Capital Management LLC | 4.42M | 4.00% | $20.6M | +14% |
| Citadel Advisors LLC | 4.19M | 3.79% | $19.6M | +67% |
| Goldman Sachs Group Inc | 3.53M | 3.19% | $16.5M | +48% |
| Wasatch Advisors LP | 3.52M | 3.19% | $16.5M | +19% |
| Two Sigma Investments, LP | 3.47M | 3.14% | $16.2M | +14% |
| Soleus Capital Management, L.P. | 3.38M | 3.06% | $15.8M | -11% |
| Silverarc Capital Management, LLC | 3.03M | 2.74% | $14.2M | +59% |
| Bank of America Corp | 2.66M | 2.40% | $12.4M | +13% |
| Geode Capital Management, LLC | 2.52M | 2.28% | $11.8M | +165% |
| Ikarian Capital, LLC | 2.43M | 2.20% | $11.4M | – |
| State Street Corp | 2.12M | 1.91% | $9.9M | +452% |
| Acadian Asset Management LLC | 1.81M | 1.63% | $8.4M | -4% |
| Candriam S.C.A. | 1.80M | 1.63% | $8.4M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CCCC insiders reported $0 of open-market purchases and $145K of sales. 85% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Kendra Adams | CFO | Sale plan | 45,173 | $2.71 | $122K | Form 4 |
| Jan 16, 2026 | Leonard Reyno | Chief Medical Officer | Sale | 10,000 | $2.22 | $22.2K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Kendra Adams | Chief Financial Officer | – | $122K | Nov 12, 2026 |
| Leonard Reyno | Chief Medical Officer | – | $22.2K | Jan 16, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CCCC short interest
Very high short interest. 35.5% of CCCC shares are sold short: about 1 share in 3. Over the last 12 reports the number of shares short went up 119%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 46.58M CCCC shares were sold short, 35.5% of the shares outstanding, up 9.0% from the report before. At the average daily volume of 3.08M shares, buying them all back would take about 15.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 46.58M | 35.47% | +9% | 3.08M | 15.1 |
| Oct 15, 2026 | 42.72M | 34.73% | +6% | 2.52M | 16.9 |
| Sep 30, 2026 | 40.40M | 32.84% | +1% | 2.29M | 17.6 |
| Sep 15, 2026 | 40.19M | 32.67% | +7% | 1.77M | 22.7 |
| Aug 31, 2026 | 37.41M | 30.41% | +10% | 2.24M | 16.7 |
| Aug 14, 2026 | 34.05M | 27.68% | +12% | 2.44M | 13.9 |
| Jul 31, 2026 | 30.43M | 24.73% | +28% | 2.74M | 11.1 |
| Jul 15, 2026 | 23.82M | 21.54% | -5% | 3.58M | 6.7 |
| Jun 30, 2026 | 25.00M | 22.61% | +12% | 4.76M | 5.2 |
| Jun 15, 2026 | 22.25M | 20.12% | +3% | 2.34M | 9.5 |
| May 29, 2026 | 21.65M | 19.58% | +2% | 2.30M | 9.4 |
| May 15, 2026 | 21.25M | 19.22% | +1% | 3.66M | 5.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
C4 Therapeutics company events
C4 Therapeutics filed 11 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Sep 25, 2026AnnouncementThe Company announced new biomarker data from its Phase 1 clinical trial of cemsidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma ( “ RRMM ”), as well as preliminary biomarker data from the first two patients in the ongoing Phase 1b trial of cemsidomide… Filing
- Aug 11, 2026ResultsReleased financial results. Filing
- Jun 24, 2026VoteReported shareholder vote results. Filing
- Jun 11, 2026AnnouncementThe Company posted on its website a poster presentation with further analysis from its fully enrolled Phase 1 trial of cemsidomide, a next-generation oral IKZF1/3 degrader, in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma, to be presented at the European… Filing
- May 15, 2026LeadershipC4 Therapeutics, Inc. determined that Mark Mossler will no longer serve as the Company’s Chief Accounting Officer, effective May 15, 2026. Filing
- May 12, 2026ResultsReleased financial results. Filing
- Apr 10, 2026RulesChanged its bylaws or articles. Filing
- Apr 9, 2026AgreementSigned an important agreement. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Jan 14, 2026AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
C4 Therapeutics financials
Famous investors that hold CCCC
4 of the 50 well-known investors we track reported holding CCCC in their latest 13F filing. The largest position is Ken Griffin's, worth $19.6M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q2 2026 | 4.19M | $19.6M | 0.0% | +67% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.21M | $4M | 0.0% | +2% |
| Israel Englander · Millennium Management | Q2 2026 | 215,386 | $1M | 0.0% | -85% |
| Steve Cohen · Point72 Asset Management | Q2 2026 | 173,965 | $812K | 0.0% | +3% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about C4 Therapeutics, Inc. (CCCC) stock
Who owns the most CCCC stock?
The largest reported owner of C4 Therapeutics, Inc. (CCCC) is Morgan Stanley, with 8.0% of the company. In total, 147 funds and institutions reported holding CCCC at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are CCCC insiders buying or selling?
In the last 12 months, CCCC insiders reported no open-market purchases and 2 sales worth $145K. The latest trade was on Nov 12, 2026. See every trade.
What is the short interest in CCCC?
As of Oct 30, 2026, 46.58M CCCC shares were sold short, 35.5% of the shares outstanding, up 9.0% from the report before. At the average daily volume of 3.08M shares, buying them all back would take about 15.1 trading days (days to cover). See the history.
Which famous investors hold CCCC?
4 of the 50 well-known investors we track reported CCCC in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $19.6M. See all holders.
Executive pay
C4 Therapeutics's chief executive was paid a total of $2.9M for the year ended Dec 31, 2025, down 37% from $4.6M the year before. In the last 12 months, C4 Therapeutics's executives and directors bought no stock on the open market and sold $145K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.